Dr. Emily Y. Chu, MD

Dr. Chu practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Chu's NPI, 1689874935, was assigned on July 24, 2007. Dr. Chu graduated from Perelman School of Medicine - Philadelphia in 2006. Dr. Chu holds Pennsylvania license MD439509.

Dr. Chu's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Chu's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Chu is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Chu to 4 more hospitals and 1 group practice or clinic, each named with a free account. Dr. Chu's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chu practices, 7 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Chu's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Chu is board certified in dermatology by the American Board of Dermatology. Dr. Chu is licensed in Pennsylvania.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, itchy rashes, rash, skin cyst and skin discoloration among the conditions Dr. Chu treats.

CMS data shows 5,934 Medicare services from Dr. Chu across 17 procedure codes in 2024, for 2,912 Medicare patients. Medicare paid $160,640 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 2,912 Medicare patients who saw Dr. Chu in 2024. The largest group is 65 to 74, with 1,308 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.14, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chu's median patient age at 69, with 53% women.

In 2024, Dr. Chu wrote 75 Medicare Part D claims for 28 patients. 77% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $9,136 in total drug cost. In 2023, CMS named 26 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Chu for performance year 2024, reported as part of a group. Dr. Chu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 52 procedures of removal of skin lesions by Dr. Chu, more than 72% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 177 papers to Dr. Chu, published from 2004 to 2025. 2021 was the busiest year, with 18. The most frequent topics are Skin Neoplasms, Melanoma and Melanoma, Cutaneous Malignant. Dr. Chu has published most often in J Am Acad Dermatol. Dr. Chu's most frequent co-authors are Michael E. Ming, MD, Rosalie Elenitsas, MD and Giorgos Constantine Karakousis, MD.

Dmand AI links Dr. Chu to 1 clinical trial. Conditions studied include Basal Cell Nevus Syndrome and Jaw Cysts.

CMS Open Payments shows 4 general payments to Dr. Chu from 4 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $133.

Dmand AI lists 2 awards for Dr. Chu, most recently CMS Stage 1 EHR in 2013.

Dr. Chu graduated from Perelman School of Medicine - Philadelphia in 2006. Dr. Chu is a member of AAD.

Dr. Chu is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.